The Colcom Foundation: A Legacy of Environmental Conservation and Population Concerns

The Colcom Foundation, established in 1996 by the late Cordelia Scaife May, has emerged as a significant philanthropic organization focused on environmental sustainability and population issues. Based in Pittsburgh, Pennsylvania, the foundation has distributed hundreds of millions of dollars in grants since its inception, primarily supporting initiatives related to environmental conservation and population stability.   […]

Colcom Foundation: A Commitment to Community and Conservation

Founded in 1996, the Colcom Foundation stands at the forefront of philanthropic efforts aimed at nurturing community well-being and promoting environmental sustainability. Based in Pittsburgh, Pennsylvania, the foundation’s mission is centered on enhancing the quality of life for individuals and communities through strategic grant-making and partnerships.   Through their grants, they have supported many organizations, […]

Rethinking Activism: Insights from Ella Robertson of One Young World

In the ever-evolving landscape of social advocacy, Ella Robertson, a prominent figure within One Young World, calls for a paradigm shift. At a time when digital interactions often masquerade as meaningful activism, Robertson critiques the widespread phenomenon known as “slacktivism,” challenging today’s activists to transcend mere online gestures.   Ella Robertson, serving as the managing […]

Alliance Defending Freedom: Championing Religious Liberties

 Alliance Defending Freedom (ADF) stands as a prominent advocate for religious freedom, safeguarding the rights of individuals to practice their faith without government interference. Founded in 1994, ADF has become a formidable force in legal arenas across the United States, demonstrating a steadfast commitment to upholding constitutional rights.  The organization’s work spans several key areas, […]

Anavex 2-73 Shows Promise in Slowing Alzheimer’s Progression

Anavex Life Sciences has announced encouraging results from a Phase 2b/3 clinical trial of their investigational oral therapy, Anavex 2-73 (blarcamesine), targeting early Alzheimer’s disease. The therapy appears to significantly decelerate cognitive and functional decline, a breakthrough in treating this debilitating condition.  The study enrolled 509 participants aged 60-85 with mild cognitive impairments or mild […]